The Effect of Ultrapure Dialysate on Clinical Outcomes and Mortality During One Year Follow-up in Patients Undergoing Hemodialysis Treatment

Basit Öğe Kaydı
dc.contributor.authorDoğan, İbrahim
dc.contributor.authorÜnal Kaya, Nur
dc.contributor.authorKayadibi, Hüseyin
dc.contributor.authorKayadibi, Hüseyin
dc.date.accessioned2021-11-01T18:15:00Z
dc.date.available2021-11-01T18:15:00Z
dc.date.issued2020
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.departmentHitit Üniversitesi, Sağlık Bilimleri Fakültesi, Sağlık Yönetimi Bölümü
dc.description.abstractObjective: We investigated the relationship between mortality and clinical status in patients with hemodialysis using ultrapure dialysate and standard dialysate. Materials and Methods: The study included 81 patients using ultrapure dialysate (Group 1) and 72 patients using standard dialysate (Group 2). Mortality rates, anemia, phosphorus, albumin, parathormone, and C-reactive protein (CRP) values were calculated as 1-year averages. Factors affecting mortality were evaluated by logistic regression analysis. Results: In Group 1, potassium, phosphorus, uric acid, CRP, and hemoglobin levels were significantly higher (p<0.001, p=0.023, p=0.010, p=0.003, p<0.001, respectively), and transferrin saturation, ferritin, and HCO3? levels were significantly lower (p=0.007, p<0.001, p=0.001, respectively) than Group 2. The erythropoietin-stimulating agent’s usage dose of Group 1 was 0.60 (0.11-1.00) ?g/kg/month and 1.30 (0.80-2.17) ?g/kg/month in Group 2 (p<0.001). Iron usage doses of Group 1 and Group 2 were 800 (425-1,275) mg/year and 1,300 (750-2,000) mg/year, respectively (p=0.002). There was no significant difference in mortality rates for the 1-year follow-up period (mortality rate in 12 patients [14.8%] in Group 1, 6 patients in Group 2 [8.9%], p=0.214). In the univariate and multivariate logistic regression analyses, age, serum Na, total protein, and CRP levels were found to be independent variables to determine mortality. Conclusion: After 1 year of short-term follow-up, Group 1 had better anemia control than Group 2 but no positive effect on mortality.
dc.identifier.citationDoğan, İ., Kaya, N. Ü., & Kayadibi, H. (2020). The Effect of Ultrapure Dialysate on Clinical Outcomes and Mortality During One Year Follow-up in Patients Undergoing Hemodialysis Treatment. Turkish journal of nephrology (Online), 29(3), 205-211.
dc.identifier.doi10.5152/turkjnephrol.2020.3979
dc.identifier.endpage211en_US
dc.identifier.issn1300-7718
dc.identifier.issn2667-4440
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85087987314
dc.identifier.scopusqualityQ4
dc.identifier.startpage205en_US
dc.identifier.urihttps://doi.org10.5152/turkjnephrol.2020.3979
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TkRFMk9USXhNUT09
dc.identifier.urihttps://hdl.handle.net/11491/7634
dc.identifier.volume29en_US
dc.identifier.wosWOS:000547335800004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorDoğan, İbrahim
dc.language.isoen
dc.relation.ispartofTurkish journal of nephrology (Online)
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectChronic kidney diseaseen_US
dc.subjectHemodialysisen_US
dc.subjectMortalityen_US
dc.titleThe Effect of Ultrapure Dialysate on Clinical Outcomes and Mortality During One Year Follow-up in Patients Undergoing Hemodialysis Treatment
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
ibrahim-dogan2020.pdf
Boyut:
427.51 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu